MarketCap
Facebook
X
Telegram
Amicus Therapeutics Langfristiger Schuldenstrom | FOLD
Langfristiger Schuldenstrom Jährlich Amicus Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.74 M | 8.46 M | 8.32 M | 8.55 M | 7.41 M | 6.87 M | 7.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 8.74 M | 6.87 M | 7.93 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Leap Therapeutics
LPTX
|
38 K | - | 368.57 % | $ 41.9 M |  USA |
 |
Zymeworks
ZYME
|
1.31 M | $ 31.45 | 2.08 % | $ 1.62 B |  Canada |
 |
ADMA Biologics
ADMA
|
1.1 M | $ 12.67 | -0.98 % | $ 3.02 B | USA |
 |
Cortexyme
CRTX
|
115 K | - | -1.05 % | $ 67.1 M | USA |
 |
Daré Bioscience
DARE
|
603 K | $ 0.69 | 1.75 % | $ 7.71 M | USA |
 |
Fate Therapeutics
FATE
|
4.56 M | $ 1.78 | -8.51 % | $ 211 M | USA |
 |
Halozyme Therapeutics
HALO
|
13.3 M | $ 103.0 | 0.08 % | $ 12.3 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
2.88 M | $ 15.34 | 0.1 % | $ 13.2 B |  China |
 |
Aptorum Group Limited
APM
|
24.4 K | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
546 K | $ 0.78 | -1.89 % | $ 81.2 M | USA |
 |
Kodiak Sciences
KOD
|
12.1 M | $ 108.01 | 0.85 % | $ 5.75 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
969 K | $ 0.02 | -54.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
1.43 M | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
437 K | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
481 K | $ 25.32 | -3.78 % | $ 1.22 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
636 K | $ 13.91 | 1.9 % | $ 1.24 B | USA |
 |
ARCA biopharma
ABIO
|
619 K | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
808 K | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
7.09 M | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
889 K | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
2.02 M | $ 0.39 | 9.06 % | $ 28.6 K | USA |
 |
Bio-Path Holdings
BPTH
|
83 K | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
116 K | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
1 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
137 K | - | -16.75 % | $ 25.8 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
113 K | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
4 K | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
294 K | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
2.1 M | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
128 K | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
512 K | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
12.6 M | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
693 K | - | 0.77 % | $ 53.4 M | USA |